• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 497648 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414683633 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414683633 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Vanda Pharmaceuticals Trading Higher on 1.6x Above-Average Volume (VNDA)

Published on Fri, 05/10/2013 - 13:15
By Peter Chu

Vanda Pharmaceuticals's stock is up 1.6% to $5.14 on heavy trading volume. Today's volume of 371,000 shares tops the average 30-day volume of 232,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Vanda Pharmaceuticals share prices have moved between a 52-week high of $5.17 and a 52-week low of $2.92 and are now trading 76% above that low price at $5.14 per share. The 200-day and 50-day moving averages have moved 0.23% higher and 2.04% higher over the past week, respectively.

Potential upside of 65.4% exists for Vanda Pharmaceuticals, based on a current level of $5.14 and analysts' average consensus price target of $8.50. The stock should find initial support at its 50-day moving average (MA) of $4.23 and further support at its 200-day MA of $3.96.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of clinical-stage, small molecule product candidates for central nervous system disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Bon-Ton Stores has the Highest Future Ea...

Below are the three companies in the Department Stores industry with the highest future ...

Churchill Downs Shares Sinking Lower, Do...

One of today's notable stocks in decline is Churchill Downs (NASDAQ:CHDN), down 3.2% to ...

National Interstate Ranks the Highest in...

Below are the three companies in the Property & Casualty Insurance industry with the hi ...

Shares of Central Pacific Financial Unde...

Central Pacific Financial (NYSE:CPF) is a company whose shares are active, trading 3.3% ...

Omnova Solutions Ranks the Highest in Te...

Below are the three companies in the Specialty Chemicals industry with the highest futu ...

Shares of KKR & Co Under Pressure, Down ...

One of today's notable stocks in decline is KKR & Co (NYSE:KKR), down 3.3% to $21.51. ...

E-Commerce China Dangdang is Among the C...

Below are the three companies in the Internet Retail industry with the highest future e ...

Shares of CIGNA Receive a Boost, Up 3.3%...

One of today's notable stocks on the rise is CIGNA (NYSE:CI), up 3.3% to $97.14. The D ...